伦瓦提尼
医学
依维莫司
舒尼替尼
彭布罗利珠单抗
内科学
肾细胞癌
肿瘤科
癌症
免疫疗法
甲状腺癌
作者
Robert J. Motzer,B. Yа. Alekseev,Sun Young Rha,Camillo Porta,Masatoshi Eto,Thomas Powles,Viktor Grünwald,Thomas E. Hutson,Evgeny Kopyltsov,María José Méndez-Vidal,Vadim Kozlov,Anna Alyasova,Sung‐Hoo Hong,Anil Kapoor,Teresa Alonso Gordoa,Jaime R. Merchan,Eric Winquist,Pablo Maroto,Jeffrey C. Goh,Miso Kim
标识
DOI：10.1056/nejmoa2035716
摘要
Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
cocodu
Nole
cdercder
东方元语
xing_xing
Kao
张欢馨
张开心
OK
aajhajkahna
aaaa
若一
乐空思
学术文献互助
七听
Criminology34
牧青
dde
yjh123
v0id
皖公网安备34019202002308
